Lurasidone hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for lurasidone hydrochloride and what is the scope of patent protection?
Lurasidone hydrochloride
is the generic ingredient in two branded drugs marketed by Sunovion Pharms Inc, Accord Hlthcare, Alembic, Alkem Labs Ltd, Amneal Pharms Co, Annora Pharma, Aurobindo Pharma Ltd, Avet Lifesciences, Dr Reddys, Invagen Pharms, Lupin Ltd, Macleods Pharms Ltd, MSN, Slate Run Pharma, Sun Pharm, Teva Pharms Usa, Torrent, Watson Labs Teva, and Zydus Pharms, and is included in nineteen NDAs. There are nine patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Lurasidone hydrochloride has sixty-nine patent family members in twenty-four countries.
There are twenty-six drug master file entries for lurasidone hydrochloride. Twenty-seven suppliers are listed for this compound. There are two tentative approvals for this compound.
Summary for lurasidone hydrochloride
International Patents: | 69 |
US Patents: | 9 |
Tradenames: | 2 |
Applicants: | 19 |
NDAs: | 19 |
Drug Master File Entries: | 26 |
Finished Product Suppliers / Packagers: | 27 |
Raw Ingredient (Bulk) Api Vendors: | 47 |
Clinical Trials: | 79 |
Patent Applications: | 121 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for lurasidone hydrochloride |
What excipients (inactive ingredients) are in lurasidone hydrochloride? | lurasidone hydrochloride excipients list |
DailyMed Link: | lurasidone hydrochloride at DailyMed |
Recent Clinical Trials for lurasidone hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
First Affiliated Hospital of Zhejiang University | Phase 4 |
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Phase 4 |
Statistics Collaborative, Inc. | Phase 2/Phase 3 |
Generic filers with tentative approvals for LURASIDONE HYDROCHLORIDE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 120MG | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | 80MG | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | 60MG | TABLET;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for lurasidone hydrochloride
Drug Class | Atypical Antipsychotic |
Medical Subject Heading (MeSH) Categories for lurasidone hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for lurasidone hydrochloride
Paragraph IV (Patent) Challenges for LURASIDONE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LATUDA | Tablets | lurasidone hydrochloride | 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg | 200603 | 14 | 2014-10-28 |
US Patents and Regulatory Information for lurasidone hydrochloride
Expired US Patents for lurasidone hydrochloride
International Patents for lurasidone hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2004259305 | Process for producing imide compound | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2012063513 | ⤷ Sign Up | |
Japan | 2011126915 | PHARMACEUTICAL COMPOSITION | ⤷ Sign Up |
South Korea | 101380088 | ⤷ Sign Up | |
South Korea | 20130122019 | PHARMACEUTICAL COMPOSITION | ⤷ Sign Up |
Slovenia | 1884242 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2004017973 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for lurasidone hydrochloride
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1884242 | 300690 | Netherlands | ⤷ Sign Up | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME |
1884242 | 551 | Finland | ⤷ Sign Up | |
1884242 | PA2014034,C1884242 | Lithuania | ⤷ Sign Up | PRODUCT NAME: LURASIDONUM; REGISTRATION NO/DATE: EU/1/14/913 20140321 |
1884242 | 2014/051 | Ireland | ⤷ Sign Up | PRODUCT NAME: LURASIDONE, PARTICULARLY A PHARMACEUTICALLY ACCEPTABLE SALT FORM AND ESPECIALLY THE HYDROCHLORIDE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/913/001-021 20140321 |
1884242 | 122014000092 | Germany | ⤷ Sign Up | PRODUCT NAME: LURASIDON, INSBESONDERE EINE PHARMAZEUTISCH VERTRAEGLICHE SALZFORM UND IM SPEZIELLEN DAS HYDROCHLORIDSALZ DAVON; REGISTRATION NO/DATE: EU/1/14/913/001-021 20140321 |
1884242 | 56/2014 | Austria | ⤷ Sign Up | PRODUCT NAME: LURASIDON, GEGEBENENFALLS IN FORM SEINER FREIEN BASE ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON.; REGISTRATION NO/DATE: EU/1/14/913 20140327 |
1884242 | C300690 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LURASIDON, OPTIONEEL IN DE VORM VAN ZIJN VRIJE BASE OF FARMACEUTISCH ACCEPTABELE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/14/913 20140321 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.